Enzyme-AMFA Therapy (NanoMedSyn)

N/A

Report date: 2025/01/26 19:24:41

Base Information

Drug NameEnzyme-AMFA Therapy (NanoMedSyn)

Drug Alias NameRecombinant Alpha-Glucosidase Conjugated with Mannose-6-Phosphate Analog (NanoMedSyn)Recombinant Alpha-Glucosidase-AMFA Conjugate (NanoMedSyn)

ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme

Mechanisms of ActionInsulin-like growth factor II receptor modulatorsMaltase-glucoamylase stimulants

TargetsMaltase-glucoamylaseInsulin-like growth factor II receptor

Therapy Area/IndicationsGlycogen Storage Disease Type II

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFrance

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNanoMedSyn

China Registration ClassN/A

Develop Information

Active CompaniesNanoMedSyn

Inactive CompaniesN/A

Active IndicationsGlycogen Storage Disease Type II

Inactive IndicationsN/A

Other Information

ATC CodeN/A